We used CCK-8 to detect cell viability following treatment with cisplatin with or without eIF5A2 siRNA and found that eIF5A2 knockdown significantly increased cisplatin sensitivity in the NSCLC cells (Figure 4(b)). The gene discussed is EIF5A2; the disease is non-small cell lung carcinoma.